PALLD and breast cancer: Extensive panel testing covering more than 40 genes is being increasingly marketed, but the diagnostic yield and action-ability remains questionable particularly for candidate genes such as TSC2 / PALLD which may not be relevant to patients with suspected hereditary breast cancer.